Treatment of new-onset primary central nervous system lymphoma in elderly patients using RMPV chemotherapy: a single-institution experience-Reference-Cited by-同舟云学术

Treatment of new-onset primary central nervous system lymphoma in elderly patients using RMPV chemotherapy: a single-institution experience

Published:2023-07-01 Issue:3 Volume:118 Page:333-339
ISSN:0925-5710
Container-title:International Journal of Hematology
language:en
Short-container-title:Int J Hematol

Author:

Yoshida Michiharu,Kato Takeharu,Hiu Takeshi^ORCID,Imaizumi Yoshitaka,Morimoto Simpei,Niino Daisuke,Yamaguchi Susumu,Baba Shiro,Ujifuku Kenta,Yoshida Koichi,Matsuo Ayaka,Morofuji Yoichi,Izumo Tsuyoshi,Okano Shinji,Miyazaki Yasushi,Matsuo Takayuki

Publisher

Springer Science and Business Media LLC

Subject

Hematology

Link

https://link.springer.com/content/pdf/10.1007/s12185-023-03632-9.pdf

Reference23 articles.

1. van der Meulen M, et al. Improved survival in primary central nervous system lymphoma up to age 70 only: a population-based study on incidence, primary treatment and survival in the Netherlands, 1989–2015. Leukemia. 2017;31(8):1822–5.

2. Houillier C, et al. Management and outcome of primary CNS lymphoma in the modern era: An LOC network study. Neurology. 2020;94(10):e1027–39.

3. Eloranta S, et al. Increasing incidence of primary central nervous system lymphoma but no improvement in survival in Sweden 2000–2013. Eur J Haematol. 2018;100(1):61–8.

4. Kasenda B, et al. First-line treatment and outcome of elderly patients with primary central nervous system lymphoma (PCNSL)–a systematic review and individual patient data meta-analysis. Ann Oncol. 2015;26(7):1305–13.

5. Mendez JS, et al. The elderly left behind-changes in survival trends of primary central nervous system lymphoma over the past 4 decades. Neuro Oncol. 2018;20(5):687–94.